




# PHARMACEUTICAL 2022

BridgeBio Pharma Inc.  
Rank 329 of 475





RealRate

# PHARMACEUTICAL 2022

BridgeBio Pharma Inc.  
Rank 329 of 475



The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 22% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is -227%, being 49% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	888,858
Cost of Goods Sold	2,735
Intangible Assets	44,934
Liabilities, Current	135,069
Liabilities, Non-Current	470,249
Other Assets	48,934
Other Compr. Net Income	23,591
Other Expenses	379
Other Liabilities	1,273,053
Other Net Income	-9,822
Property and Equipment	30,066
Research and Development	451,024
Revenues	69,716
Selling, General and Administrative Expense	192,210

Output Variable	Value in 1000 USD
Assets	1,012,792
Liabilities	1,878,371
Expenses	646,348
Stockholders Equity	-865,579
Net Income	-586,454
Comprehensive Net Income	-574,658
Economic Capital Ratio	-227%



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)